Kymera Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $11,476 | $22,100 | $7,394 | $3,741 |
Gross Profit | 9,392 | 22,100 | 7,394 | 3,741 |
EBITDA | -84,557 | -63,461 | -68,706 | -60,440 |
EBIT | -86,641 | -65,509 | -70,693 | -62,427 |
Net Income | -76,614 | -65,581 | -70,752 | -62,487 |
Net Change In Cash | 11,476 | 22,100 | 7,394 | 3,741 |
Free Cash Flow | -60,579 | -79,617 | -62,720 | -50,001 |
Cash | 335,816 | 89,966 | 120,256 | 110,718 |
Basic Shares | 80,449 | 80,146 | 79,987 | 76,125 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $47,072 | $78,592 | $46,826 | $72,832 |
Gross Profit | 47,072 | 78,592 | 43,849 | 70,435 |
EBITDA | -216,235 | -143,201 | -151,655 | -97,645 |
EBIT | -223,608 | -146,766 | -154,632 | -100,042 |
Net Income | -223,858 | -146,962 | -151,831 | -97,995 |
Net Change In Cash | 47,072 | 78,592 | 46,826 | 72,832 |
Cost of Revenue | 20,433 | 21,499 | ||
Free Cash Flow | -207,339 | -137,306 | -155,921 | -130,543 |
Cash | 120,256 | 109,966 | 68,395 | 47,976 |
Basic Shares | 75,043 | 58,365 | 53,933 | 47,989 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.95 |
2025-03-31 | -$0.82 |
2024-12-31 | -$0.89 |
2024-09-30 | -$0.82 |
